Johannes T. H. Nielen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johannes T. H. Nielen has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Coen D. A. Stehouwer
Department of Chronic Diseases and Metabolism, KU Leuven, ON1bis Herestraat 49 - Box 902, Louvain, 3000, Belgium
5 shared publications - Frank de Vries
Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, the Netherlands
3 shared publications - Nikki Christina Clasina Werkman
Department of Clinical Pharmacy, Franciscus, Rotterdam and Schiedam, The Netherlands
3 shared publications - Annelies Boonen
Care and Public Health Research Institute (CAPHRI), Maastricht University , Maastricht
2 shared publications - Annemarie Koster
Department of Social Medicine, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands
2 shared publications - Fatma Karapinar-Çarkit
Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, the Netherlands
2 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Springer Nature in Drugs & Aging
- Vol. 43 (10) , 933-943
Creating Awareness of preScribing Cascades and Managing Adverse Drug Effects (CASC-ADE) Tool: Appraisal by Future End Users
Background Despite increasing attention for prescribing cascades, healthcare providers (HCP) need tools for taking action. We developed a tool, comprising fact sheets that summarise background information and provide guidance for recognising, managing, and preventing specific prescribing cascades. The aim of this study was to explore end users’ appraisal of the initial version of this ‘Creating Awareness of prescribing Cascades and managing Adverse Drug Effects’ (CASC-ADE) tool. Methods A cross-sectional study was conducted using an online questionnaire including 15 items (13 scored on 7-point Likert scales, 2 on a 7-point bipolar scale, with a score of 4 being adequate), covering four domains: purpose, rigour, usability, and usefulness. The questionnaire, alongside at least one fact sheet, was sent to a convenience sample of HCPs, medical and pharmacy students. Suggestions for improvement could be made by respondents. Descriptive statistics were evaluated separately for HCPs and students. Results The study included 17 HCPs (9 pharmacists, 8 clinicians) and 12 students (6 pharmacy, 6 medical). All items received positive median scores: Likert scale items between 5 and 7 for HCPs and 5 and 6 for students, and bipolar scale items 4 for HCPs and 4–4.5 for students. Highest scores were seen for purpose, usability, and usefulness for recognising prescribing cascades (median 6–7). Usefulness for managing and preventing prescribing cascades received slightly lower scores (median 5–6). Fifteen HCPs and nine students were positive about using the tool in practice but some mentioned this would depend on its practical implementation. A few respondents suggested including more specific guidance for taking action. Conclusions The initial CASC-ADE tool was positively appraised across the assessed domains by the HCPs and students. Further research is needed to assess whether its use will improve recognition, management and prevention of prescribing cascades.
- 9 September 2026
- Published by Springer Nature in Drugs & Aging
- Vol. 43 (10) , 933-943
Open AccessCreating Awareness of preScribing Cascades and Managing Adverse Drug Effects (CASC-ADE) Tool: Appraisal by Future End Users
Background Despite increasing attention for prescribing cascades, healthcare providers (HCP) need tools for taking action. We developed a tool, comprising fact sheets that summarise background information and provide guidance for recognising, managing, and preventing specific prescribing cascades. The aim of this study was to explore end users’ appraisal of the initial version of this ‘Creating Awareness of prescribing Cascades and managing Adverse Drug Effects’ (CASC-ADE) tool. Methods A cross-sectional study was conducted using an online questionnaire including 15 items (13 scored on 7-point Likert scales, 2 on a 7-point bipolar scale, with a score of 4 being adequate), covering four domains: purpose, rigour, usability, and usefulness. The questionnaire, alongside at least one fact sheet, was sent to a convenience sample of HCPs, medical and pharmacy students. Suggestions for improvement could be made by respondents. Descriptive statistics were evaluated separately for HCPs and students. Results The study included 17 HCPs (9 pharmacists, 8 clinicians) and 12 students (6 pharmacy, 6 medical). All items received positive median scores: Likert scale items between 5 and 7 for HCPs and 5 and 6 for students, and bipolar scale items 4 for HCPs and 4–4.5 for students. Highest scores were seen for purpose, usability, and usefulness for recognising prescribing cascades (median 6–7). Usefulness for managing and preventing prescribing cascades received slightly lower scores (median 5–6). Fifteen HCPs and nine students were positive about using the tool in practice but some mentioned this would depend on its practical implementation. A few respondents suggested including more specific guidance for taking action. Conclusions The initial CASC-ADE tool was positively appraised across the assessed domains by the HCPs and students. Further research is needed to assess whether its use will improve recognition, management and prevention of prescribing cascades.
- Open Access
- 17 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 5524-5537
Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose‐lowering drugs with machine learning—The Maastricht study
Background: Despite the heterogeneity of type 2 diabetes (T2D), all patients are treated according to the same guideline. Some people have more difficulty reaching treatment goals (adequate glycaemic control) and maintaining quality of life (QoL). Therefore, a prediction model identifying who is unlikely to reach these goals within the next year would be useful to allow specific attention to these people. Aim: To investigate if machine learning algorithms can predict which individuals are unlikely to reach glycaemic control and likely to deteriorate in QoL in 1 year. Methods: We used data from The Maastricht Study, including 842 people with T2D and information on HbA1c values, and 964 people with T2D and information on QoL. We evaluated several machine learning algorithms with feature selection methods and hyperparameter tuning in fivefold cross‐validation for the corresponding outcomes. Results: The prediction of inadequate glycaemic control showed good performance. The support vector machine classifier performed best in terms of accuracy (0.76 (95% CI 0.71–0.79)), precision (0.79 (95% CI 0.71–0.83)) and area under the receiver operating characteristic curve (AUC‐ROC) (0.85 (95% CI 0.80–0.89)). The multi‐layer perceptron classifier performed best in terms of recall (0.72 (95% CI 0.64–0.79)) and F1‐score (0.73 (95% CI 0.64–0.79)). The prediction of deterioration in QoL showed inadequate performance and did not seem feasible. Conclusion: Prediction of glycaemic control after 1 year in T2D is feasible with good model performance. However, the prediction of deterioration in QoL remains a challenge and needs further work.
- 17 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 5524-5537
Open AccessPrediction of glycaemic control and quality of life in people with type 2 diabetes using glucose‐lowering drugs with machine learning—The Maastricht study
Background: Despite the heterogeneity of type 2 diabetes (T2D), all patients are treated according to the same guideline. Some people have more difficulty reaching treatment goals (adequate glycaemic control) and maintaining quality of life (QoL). Therefore, a prediction model identifying who is unlikely to reach these goals within the next year would be useful to allow specific attention to these people. Aim: To investigate if machine learning algorithms can predict which individuals are unlikely to reach glycaemic control and likely to deteriorate in QoL in 1 year. Methods: We used data from The Maastricht Study, including 842 people with T2D and information on HbA1c values, and 964 people with T2D and information on QoL. We evaluated several machine learning algorithms with feature selection methods and hyperparameter tuning in fivefold cross‐validation for the corresponding outcomes. Results: The prediction of inadequate glycaemic control showed good performance. The support vector machine classifier performed best in terms of accuracy (0.76 (95% CI 0.71–0.79)), precision (0.79 (95% CI 0.71–0.83)) and area under the receiver operating characteristic curve (AUC‐ROC) (0.85 (95% CI 0.80–0.89)). The multi‐layer perceptron classifier performed best in terms of recall (0.72 (95% CI 0.64–0.79)) and F1‐score (0.73 (95% CI 0.64–0.79)). The prediction of deterioration in QoL showed inadequate performance and did not seem feasible. Conclusion: Prediction of glycaemic control after 1 year in T2D is feasible with good model performance. However, the prediction of deterioration in QoL remains a challenge and needs further work.
- Open Access
- 2 June 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (1) , e70063
Real‐World Complexity of Prescribing Cascades
Prescribing cascades occur when an adverse drug reaction (ADR) to one medication is treated with additional medication. Most literature focusses on this simplistic singular concept of one medication followed by another. However, ADRs in clinical practice may appear less straightforward, making prescribing cascades difficult to identify and deprescribe. More insight is needed into the real‐world complexity of prescribing cascades, since they may negatively impact both patients and the healthcare system. This article aims to provide exemplary cases of the real‐world complexity of prescribing cascades and explores strategies to identify, mitigate and prevent them. The real‐world cases discussed highlight the multifaceted nature of prescribing cascades in clinical practice. They show several factors contributing to the challenges in recognizing ADRs and preventing prescribing cascades, including misinterpretation of ADRs, fragmented healthcare systems and accumulation of pharmacological effects and comorbidities within an individual patient. Several strategies are recommended to improve identification, mitigation and prevention of prescribing cascades. Although educating patients and healthcare providers (HCPs) can help bridge the knowledge gap, additional strategies are needed. Implementing supportive tools to deprescribe, enhanced communication among HCPs and patients regarding ADRs and rationale for medication changes, and monitoring patients for ADRs are considered the most promising strategies.
- 2 June 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (1) , e70063
Open AccessReal‐World Complexity of Prescribing Cascades
Prescribing cascades occur when an adverse drug reaction (ADR) to one medication is treated with additional medication. Most literature focusses on this simplistic singular concept of one medication followed by another. However, ADRs in clinical practice may appear less straightforward, making prescribing cascades difficult to identify and deprescribe. More insight is needed into the real‐world complexity of prescribing cascades, since they may negatively impact both patients and the healthcare system. This article aims to provide exemplary cases of the real‐world complexity of prescribing cascades and explores strategies to identify, mitigate and prevent them. The real‐world cases discussed highlight the multifaceted nature of prescribing cascades in clinical practice. They show several factors contributing to the challenges in recognizing ADRs and preventing prescribing cascades, including misinterpretation of ADRs, fragmented healthcare systems and accumulation of pharmacological effects and comorbidities within an individual patient. Several strategies are recommended to improve identification, mitigation and prevention of prescribing cascades. Although educating patients and healthcare providers (HCPs) can help bridge the knowledge gap, additional strategies are needed. Implementing supportive tools to deprescribe, enhanced communication among HCPs and patients regarding ADRs and rationale for medication changes, and monitoring patients for ADRs are considered the most promising strategies.
- Open Access
- 1 July 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (9) , 3764-3780
Incretin‐based therapy and the risk of diabetic foot ulcers and related events
Aim: To investigate the effect of dipeptidyl peptidase‐4 inhibitors (DPP4‐Is) and glucagon‐like peptide‐1 receptor agonists (GLP1‐RAs) on diabetic foot ulcer (DFU) and DFU‐related outcomes (lower limb amputation [LLA], DFU‐related hospitalization and mortality). Methods: We performed a cohort study with data from the Clinical Practice Research Datalink Aurum database with linkage to hospital data. We included people with type 2 diabetes starting treatment with metformin. Then we propensity score matched new users of DPP4‐Is and sulphonylureas ( N = 98 770), and new users of GLP1‐RAs and insulin ( N = 25 422). Cox proportional hazards models estimated the hazard ratios (HRs) for the outcomes. Results: We observed a lower risk of DFU with both DPP4‐I use versus sulphonylurea use (HR 0.88, 95% confidence interval [CI]: 0.79‐0.97) and GLP1‐RA use versus insulin use (HR 0.44, 95% CI: 0.32‐0.60) for short‐term exposure (≤ 400 days) and HR 0.74 (95% CI: 0.60‐0.92) for long‐term exposure (>400 days). Furthermore, the risks of hospitalization and mortality were lower with both DPP4‐I use and GLP1‐RA use. The risk of LLA was lower with GLP1‐RA use. The results remained consistent across several sensitivity analyses. Conclusions: Incretin‐based therapy was associated with a lower risk of DFU and DFU‐related outcomes. This suggests benefits for the use of this treatment in people at risk of DFU.
- 1 July 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (9) , 3764-3780
Open AccessIncretin‐based therapy and the risk of diabetic foot ulcers and related events
Aim: To investigate the effect of dipeptidyl peptidase‐4 inhibitors (DPP4‐Is) and glucagon‐like peptide‐1 receptor agonists (GLP1‐RAs) on diabetic foot ulcer (DFU) and DFU‐related outcomes (lower limb amputation [LLA], DFU‐related hospitalization and mortality). Methods: We performed a cohort study with data from the Clinical Practice Research Datalink Aurum database with linkage to hospital data. We included people with type 2 diabetes starting treatment with metformin. Then we propensity score matched new users of DPP4‐Is and sulphonylureas ( N = 98 770), and new users of GLP1‐RAs and insulin ( N = 25 422). Cox proportional hazards models estimated the hazard ratios (HRs) for the outcomes. Results: We observed a lower risk of DFU with both DPP4‐I use versus sulphonylurea use (HR 0.88, 95% confidence interval [CI]: 0.79‐0.97) and GLP1‐RA use versus insulin use (HR 0.44, 95% CI: 0.32‐0.60) for short‐term exposure (≤ 400 days) and HR 0.74 (95% CI: 0.60‐0.92) for long‐term exposure (>400 days). Furthermore, the risks of hospitalization and mortality were lower with both DPP4‐I use and GLP1‐RA use. The risk of LLA was lower with GLP1‐RA use. The results remained consistent across several sensitivity analyses. Conclusions: Incretin‐based therapy was associated with a lower risk of DFU and DFU‐related outcomes. This suggests benefits for the use of this treatment in people at risk of DFU.
- Open Access
- 11 January 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (4) , 690-702
Disease severity-based subgrouping of type 2 diabetes does not parallel differences in quality of life: the Maastricht Study
Aims/hypothesis: Type 2 diabetes is a highly heterogeneous disease for which new subgroups (‘clusters’) have been proposed based on disease severity: moderate age-related diabetes (MARD), moderate obesity-related diabetes (MOD), severe insulin-deficient diabetes (SIDD) and severe insulin-resistant diabetes (SIRD). It is unknown how disease severity is reflected in terms of quality of life in these clusters. Therefore, we aimed to investigate the cluster characteristics and cluster-wise evolution of quality of life in the previously defined clusters of type 2 diabetes. Methods: We included individuals with type 2 diabetes from the Maastricht Study, who were allocated to clusters based on a nearest centroid approach. We used logistic regression to evaluate the cluster-wise association with diabetes-related complications. We plotted the evolution of HbA1c levels over time and used Kaplan–Meier curves and Cox regression to evaluate the cluster-wise time to reach adequate glycaemic control. Quality of life based on the Short Form 36 (SF-36) was also plotted over time and adjusted for age and sex using generalised estimating equations. The follow-up time was 7 years. Analyses were performed separately for people with newly diagnosed and already diagnosed type 2 diabetes. Results: We included 127 newly diagnosed and 585 already diagnosed individuals. Already diagnosed people in the SIDD cluster were less likely to reach glycaemic control than people in the other clusters, with an HR compared with MARD of 0.31 (95% CI 0.22, 0.43). There were few differences in the mental component score of the SF-36 in both newly and already diagnosed individuals. In both groups, the MARD cluster had a higher physical component score of the SF-36 than the other clusters, and the MOD cluster scored similarly to the SIDD and SIRD clusters. Conclusions/interpretation: Disease severity suggested by the clusters of type 2 diabetes is not entirely reflected in quality of life. In particular, the MOD cluster does not appear to be moderate in terms of quality of life. Use of the suggested cluster names in practice should be carefully considered, as the non-neutral nomenclature may affect disease perception in individuals with type 2 diabetes and their healthcare providers. Graphical
- 11 January 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (4) , 690-702
Open AccessDisease severity-based subgrouping of type 2 diabetes does not parallel differences in quality of life: the Maastricht Study
Aims/hypothesis: Type 2 diabetes is a highly heterogeneous disease for which new subgroups (‘clusters’) have been proposed based on disease severity: moderate age-related diabetes (MARD), moderate obesity-related diabetes (MOD), severe insulin-deficient diabetes (SIDD) and severe insulin-resistant diabetes (SIRD). It is unknown how disease severity is reflected in terms of quality of life in these clusters. Therefore, we aimed to investigate the cluster characteristics and cluster-wise evolution of quality of life in the previously defined clusters of type 2 diabetes. Methods: We included individuals with type 2 diabetes from the Maastricht Study, who were allocated to clusters based on a nearest centroid approach. We used logistic regression to evaluate the cluster-wise association with diabetes-related complications. We plotted the evolution of HbA1c levels over time and used Kaplan–Meier curves and Cox regression to evaluate the cluster-wise time to reach adequate glycaemic control. Quality of life based on the Short Form 36 (SF-36) was also plotted over time and adjusted for age and sex using generalised estimating equations. The follow-up time was 7 years. Analyses were performed separately for people with newly diagnosed and already diagnosed type 2 diabetes. Results: We included 127 newly diagnosed and 585 already diagnosed individuals. Already diagnosed people in the SIDD cluster were less likely to reach glycaemic control than people in the other clusters, with an HR compared with MARD of 0.31 (95% CI 0.22, 0.43). There were few differences in the mental component score of the SF-36 in both newly and already diagnosed individuals. In both groups, the MARD cluster had a higher physical component score of the SF-36 than the other clusters, and the MOD cluster scored similarly to the SIDD and SIRD clusters. Conclusions/interpretation: Disease severity suggested by the clusters of type 2 diabetes is not entirely reflected in quality of life. In particular, the MOD cluster does not appear to be moderate in terms of quality of life. Use of the suggested cluster names in practice should be carefully considered, as the non-neutral nomenclature may affect disease perception in individuals with type 2 diabetes and their healthcare providers. Graphical
- Open Access
- 29 June 2023
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 22 (1) , 1-14
The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study
Background: Numerous studies have investigated the potential association of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) with an increased risk of lower limb amputations (LLAs), but have produced conflicting results. Particularly studies comparing SGLT2-Is to glucagon-like peptide-1 receptor agonists (GLP1-RAs) seem to find a higher LLA risk with SGLT2-I use. This raises the question whether the results are driven by a protective GLP1-RA-effect rather than a harmful SGLT2-I-effect. GLP1-RAs could promote wound healing and therefore reduce the risk of LLAs, but the associations between both drug classes and LLA remain uncertain. Therefore, the aim of the current study was to investigate the risk of LLA and diabetic foot ulcer (DFU) with SGLT2-I use and GLP1-RA use versus sulfonylurea use. Methods: A retrospective population-based cohort study was conducted using data from the Danish National Health Service (2013–2018). The study population (N = 74,475) consisted of type 2 diabetes patients aged 18 + who received a first ever prescription of an SGLT2-I, GLP1-RA or sulfonylurea. The date of the first prescription defined the start of follow-up. Time-varying Cox proportional hazards models estimated the hazard ratios (HRs) of LLA and DFU with current SGLT2-I use and GLP1-RA use versus current SU use. The models were adjusted for age, sex, socio-economic variables, comorbidities and concomitant drug use. Results: Current SGLT2-I use was not associated with a higher risk of LLA versus sulfonylureas {adjusted HR 1.10 [95% confidence interval (CI) 0.71–1.70]}. Current GLP1-RA use, on the other hand, was associated with a lower risk of LLA [adjusted HR 0.57 (95%CI 0.39–0.84)] compared to sulfonylureas. The risk of DFU was similar to that with sulfonylureas with both exposures of interest. Conclusion: SGLT2-I use was not associated with a higher risk of LLA, but GLP1-RAs with a lower risk of LLA. Previous studies reporting a higher risk of LLA with SGLT2-I use compared to GLP1-RA use might have been looking at a protective GLP1-RA effect, rather than a harmful SGLT2-I effect.
- 29 June 2023
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 22 (1) , 1-14
Open AccessThe use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study
Background: Numerous studies have investigated the potential association of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) with an increased risk of lower limb amputations (LLAs), but have produced conflicting results. Particularly studies comparing SGLT2-Is to glucagon-like peptide-1 receptor agonists (GLP1-RAs) seem to find a higher LLA risk with SGLT2-I use. This raises the question whether the results are driven by a protective GLP1-RA-effect rather than a harmful SGLT2-I-effect. GLP1-RAs could promote wound healing and therefore reduce the risk of LLAs, but the associations between both drug classes and LLA remain uncertain. Therefore, the aim of the current study was to investigate the risk of LLA and diabetic foot ulcer (DFU) with SGLT2-I use and GLP1-RA use versus sulfonylurea use. Methods: A retrospective population-based cohort study was conducted using data from the Danish National Health Service (2013–2018). The study population (N = 74,475) consisted of type 2 diabetes patients aged 18 + who received a first ever prescription of an SGLT2-I, GLP1-RA or sulfonylurea. The date of the first prescription defined the start of follow-up. Time-varying Cox proportional hazards models estimated the hazard ratios (HRs) of LLA and DFU with current SGLT2-I use and GLP1-RA use versus current SU use. The models were adjusted for age, sex, socio-economic variables, comorbidities and concomitant drug use. Results: Current SGLT2-I use was not associated with a higher risk of LLA versus sulfonylureas {adjusted HR 1.10 [95% confidence interval (CI) 0.71–1.70]}. Current GLP1-RA use, on the other hand, was associated with a lower risk of LLA [adjusted HR 0.57 (95%CI 0.39–0.84)] compared to sulfonylureas. The risk of DFU was similar to that with sulfonylureas with both exposures of interest. Conclusion: SGLT2-I use was not associated with a higher risk of LLA, but GLP1-RAs with a lower risk of LLA. Previous studies reporting a higher risk of LLA with SGLT2-I use compared to GLP1-RA use might have been looking at a protective GLP1-RA effect, rather than a harmful SGLT2-I effect.
- Open Access
- 1 June 2018
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (Suppl 2) , 1604
AB0959 Consumption of dairy products in relation to presence of clinical knee osteoarthritis: the maastricht study
Background Observational studies showed inverse associations between milk consumption and knee osteoarthritis (knee OA).1, 2 There is lack of information on the role of specific other dairy product categories. Objectives To explore the association between dairy consumption and presence of clinical knee OA in individuals aged 40–75 year participating in the Maastricht Study. Methods Presence of clinical knee OA was defined according to a slightly modified version of the American College of Rheumatology (ACR) clinical classification criteria.3 Data on dairy consumption was appraised by a 253-item Food Frequency Questionnaire covering 47 dairy products with categorization on fat content, fermentation or dairy type. Multivariable logistic regression analyses were performed to estimate odd ratios (ORs) and 95% confidence intervals (95% CI), while correcting for relevant factors. Results Of the 3010 participants included in this study, 427 individuals (14%) were classified as having clinical knee OA. Significant inverse associations were observed between presence of clinical knee OA and intake of full-fat dairy and Dutch, primarily semi-hard, cheese, with OR for the highest compared to the lowest tertile of intake of 0.68 (95%CI 0.50–0.92) for full-fat dairy, and 0.75 (95%CI 0.56–0.99) for Dutch cheese. No significant associations were found for other dairy product categories. Conclusions In this Dutch population, higher intake of full-fat dairy and Dutch cheese, but not milk, was cross-sectionally associated with lower presence of clinical knee OA. Prospective studies need to assess the relationship between dairy consumption, and in particular semi-hard cheeses, with incident knee OA. References [1] Kacar C, et al. Clin Exp Rheumatol. 2004;22(4):473–6. [2] Lu B, et al. Arthritis Care Res. 2014;66(6):802–9. [3] Altman R, et al. Arthritis Rheum. 1986;29(8):1039–49. Acknowledgements The authors thank all the voluntary participants from the Maastricht Study as well as the funding bodies. Disclosure of Interest K. Denissen: None declared, A. Boonen: None declared, J. Nielen: None declared, A. Feitsma Employee of: FrieslandCampina, a dairy company, E. van den Heuvel Employee of: FrieslandCampina, a dairy company, P. Emans: None declared, S. Sep: None declared, C. Stehouwer: None declared, M. van Dongen: None declared, P. Dagnelie: None declared, S. Eussen: None declared
- 1 June 2018
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (Suppl 2) , 1604
Open AccessAB0959 Consumption of dairy products in relation to presence of clinical knee osteoarthritis: the maastricht study
Background Observational studies showed inverse associations between milk consumption and knee osteoarthritis (knee OA).1, 2 There is lack of information on the role of specific other dairy product categories. Objectives To explore the association between dairy consumption and presence of clinical knee OA in individuals aged 40–75 year participating in the Maastricht Study. Methods Presence of clinical knee OA was defined according to a slightly modified version of the American College of Rheumatology (ACR) clinical classification criteria.3 Data on dairy consumption was appraised by a 253-item Food Frequency Questionnaire covering 47 dairy products with categorization on fat content, fermentation or dairy type. Multivariable logistic regression analyses were performed to estimate odd ratios (ORs) and 95% confidence intervals (95% CI), while correcting for relevant factors. Results Of the 3010 participants included in this study, 427 individuals (14%) were classified as having clinical knee OA. Significant inverse associations were observed between presence of clinical knee OA and intake of full-fat dairy and Dutch, primarily semi-hard, cheese, with OR for the highest compared to the lowest tertile of intake of 0.68 (95%CI 0.50–0.92) for full-fat dairy, and 0.75 (95%CI 0.56–0.99) for Dutch cheese. No significant associations were found for other dairy product categories. Conclusions In this Dutch population, higher intake of full-fat dairy and Dutch cheese, but not milk, was cross-sectionally associated with lower presence of clinical knee OA. Prospective studies need to assess the relationship between dairy consumption, and in particular semi-hard cheeses, with incident knee OA. References [1] Kacar C, et al. Clin Exp Rheumatol. 2004;22(4):473–6. [2] Lu B, et al. Arthritis Care Res. 2014;66(6):802–9. [3] Altman R, et al. Arthritis Rheum. 1986;29(8):1039–49. Acknowledgements The authors thank all the voluntary participants from the Maastricht Study as well as the funding bodies. Disclosure of Interest K. Denissen: None declared, A. Boonen: None declared, J. Nielen: None declared, A. Feitsma Employee of: FrieslandCampina, a dairy company, E. van den Heuvel Employee of: FrieslandCampina, a dairy company, P. Emans: None declared, S. Sep: None declared, C. Stehouwer: None declared, M. van Dongen: None declared, P. Dagnelie: None declared, S. Eussen: None declared
- Open Access
- 24 May 2018
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 24 (1) , 37-45
The Association Between β-Blocker Use and Cardiorespiratory Fitness: The Maastricht Study
Purpose: β-Blockers (BBs) have been associated with a reduced cardiorespiratory fitness (CRF). This is possibly caused by inhibition of β2-receptors in the airways. However, there are limited data available on β-receptor selectivity and CRF. We therefore aimed to assess the association between BB use and CRF and to assess the association between β-receptor selectivity and CRF.Methods: Participants in the Maastricht Study were aged between 40 and 75 years. Exposure to BB use was determined by use of pharmacy records. General linear models were used to obtain adjusted means of 2 proxies for CRF: covered distance during the 6-minute walk test (6MWT) and estimated maximum power output adjusted for body mass ( Wmaxkg−1) during the submaximal cycle ergometer test. Adjusted means were compared between current, past, and never BB users. Current users were subsequently stratified by β-receptor selectivity and dose.Results: Compared to never use, current use was associated with a lower CRF, based on the 6MWT (current use: 569.7 m; never use: 580.4 m [ P = .010]), but not based on the cycling test (current use: 2.14 W kg−1; never use: 2.13 W kg−1[ P = .690]). There was no difference between current selective and current nonselective BB use.Conclusion: β-Blockers use was associated with CRF based on the 6MWT but not the cycling test. There was no difference between current selective and nonselective BB users, possibly due to the small number of nonselective BB users, differential underlying diseases, other pharmacological properties, and limitations related to the proxies of the outcome.
- 24 May 2018
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 24 (1) , 37-45
Open AccessThe Association Between β-Blocker Use and Cardiorespiratory Fitness: The Maastricht Study
Purpose: β-Blockers (BBs) have been associated with a reduced cardiorespiratory fitness (CRF). This is possibly caused by inhibition of β2-receptors in the airways. However, there are limited data available on β-receptor selectivity and CRF. We therefore aimed to assess the association between BB use and CRF and to assess the association between β-receptor selectivity and CRF.Methods: Participants in the Maastricht Study were aged between 40 and 75 years. Exposure to BB use was determined by use of pharmacy records. General linear models were used to obtain adjusted means of 2 proxies for CRF: covered distance during the 6-minute walk test (6MWT) and estimated maximum power output adjusted for body mass ( Wmaxkg−1) during the submaximal cycle ergometer test. Adjusted means were compared between current, past, and never BB users. Current users were subsequently stratified by β-receptor selectivity and dose.Results: Compared to never use, current use was associated with a lower CRF, based on the 6MWT (current use: 569.7 m; never use: 580.4 m [ P = .010]), but not based on the cycling test (current use: 2.14 W kg−1; never use: 2.13 W kg−1[ P = .690]). There was no difference between current selective and current nonselective BB use.Conclusion: β-Blockers use was associated with CRF based on the 6MWT but not the cycling test. There was no difference between current selective and nonselective BB users, possibly due to the small number of nonselective BB users, differential underlying diseases, other pharmacological properties, and limitations related to the proxies of the outcome.
- 1 February 2018
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 26 (2) , 202-210
Disease burden of knee osteoarthritis patients with a joint replacement compared to matched controls: a population-based analysis of a Dutch medical claims database
- 1 February 2018
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 26 (2) , 202-210
Disease burden of knee osteoarthritis patients with a joint replacement compared to matched controls: a population-based analysis of a Dutch medical claims database